DBV Technologies vs Molecular Partners
DBVT and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBVT and MOLN compare
DBV Technologies grew revenue faster over the last twelve months (−31.6% versus −100% for Molecular Partners).
DBV Technologies scores higher on the StockData Score (6 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBVT | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | – |
| Share price | $11.51 | $3.09 |
| Change, 1 year | −17.6% | −27.3% |
| Change, 5 years | 88.1% | −70.4% |
| Beta (5Y) | 0.58 | 0.90 |
| Employees | 125 | 34 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 943× | – |
| P/B | 24.4× | – |
| FCF yield | −5.3% | – |
| Growth | ||
| Revenue growth (TTM) | −31.6% (better) | −100% |
| Revenue growth, 5Y average | −13.0% | – |
| Profitability | ||
| Operating margin | −5432% | – |
| Net margin | −5405% | – |
| FCF margin | −4998% | – |
| Return on equity | −206% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 3.24 | 7.27 (better) |
| Altman Z-score | 27.93 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 6.8% | 8.9% |
| Held by insiders | 12.1% | 0.00% |
| Insider net buying, 12 months | −$15.5M | – |
| Superinvestors holding | 1 | – |
Go deeper
- DBVT stock overview
- DBVT income statement
- DBVT valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.